Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
248
TGA:248
Drug Approvals
OMTRALO 49/51 sacubitril/valsartan (combined as a sodium salt hydrate complex) 48.6/51.4 mg film-coated tablet blister pack (475686)
- Product Name
- OMTRALO 49/51 sacubitril/valsartan (combined as a sodium salt hydrate complex) 48.6/51.4 mg film-coated tablet blister pack
- Approval Date
- Mar 31, 2025
TGA
OMTRALO 97/103 sacubitril/valsartan (combined as a sodium salt hydrate complex) 97.2/102.8 mg film-coated tablet blister pack (474065)
- Product Name
- OMTRALO 97/103 sacubitril/valsartan (combined as a sodium salt hydrate complex) 97.2/102.8 mg film-coated tablet blister pack
- Approval Date
- Mar 31, 2025
TGA
OMTRALO 24/26 sacubitril/valsartan (combined as a sodium salt hydrate complex) 24.3/25.7 mg film-coated tablet blister pack (475687)
- Product Name
- OMTRALO 24/26 sacubitril/valsartan (combined as a sodium salt hydrate complex) 24.3/25.7 mg film-coated tablet blister pack
- Approval Date
- Mar 31, 2025
TGA
LIORESAL 10 baclofen 10mg tablet blister pack (462705)
- Product Name
- LIORESAL 10 baclofen 10 mg tablet blister pack
- Approval Date
- Jan 21, 2025
TGA
Cellular Therapies - T Cells - Tisagenlecleucel, cryopreserved - T - Kymriah - Novartis Pharmaceuticals Australia Pty Ltd - Suspension - Bag (475975)
- Product Name
- T Cells - Tisagenlecleucel, cryopreserved - T - Kymriah
- Approval Date
- Jan 16, 2025
TGA
Cellular Therapies - T Cells - Tisagenlecleucel, cryopreserved - T - Kymriah - Novartis Pharmaceuticals Australia Pty Ltd - Suspension - Bag (475976)
- Product Name
- T Cells - Tisagenlecleucel, cryopreserved - T - Kymriah
- Approval Date
- Jan 16, 2025
TGA
SIMULECT basiliximab (rmc) 20mg powder for injection vial (440470)
- Product Name
- SIMULECT basiliximab (rmc) 20mg powder for injection vial
- Approval Date
- Oct 22, 2024
TGA
XOLAIR omalizumab (rch) 300 mg solution for injection pre-filled pen (429512)
- Product Name
- XOLAIR omalizumab (rch) 300 mg solution for injection pre-filled pen
- Approval Date
- Sep 4, 2024
TGA
XOLAIR omalizumab (rch) 300 mg solution for injection pre-filled syringe (429450)
- Product Name
- XOLAIR omalizumab (rch) 300 mg solution for injection pre-filled syringe
- Approval Date
- Sep 4, 2024
TGA
XOLAIR omalizumab (rch) 150 mg solution for injection pre-filled pen (429511)
- Product Name
- XOLAIR omalizumab (rch) 150 mg solution for injection pre-filled pen
- Approval Date
- Sep 4, 2024
TGA
- Prev
- 1
- 2
- 3
- 4
- 5
- 25
- Next
Clinical Trials
No trials found
News
No news found